Clay Siegall is a U.S based biotechnology experts who has gained global respect due to his positive contributions to the improvement of cancer treatments. He is also skilled in genetics and has been using his expertise in developing gene-based therapies. Siegall kicked off his career about three decades ago and had served different institutions in the private and public sectors. He currently acts as the CEO of Seattle Genetics, which is a biotechnology research organization that he co-founded in 1998. The firm has been working towards the development of effective cancer therapies that do not cause health problems to the patients. Chemotherapies are known to have side effects such as loss of hair and infertility.
Seattle Genetics is currently a thriving research hub that comprises of a couple of the biotechnology experts who are committed to developing the best cancer treatments. The FDA has approved some targeted cancer therapies that have been created by the company. Seattle Genetics is greatly appreciated for being the founder of the antibody drug conjugates technology that various pharmaceutical corporations use in making cancer drugs. The firm generated revenue from the technology by licensing manufacturers to use its technology, selling ADC-based drugs, and working with various companies to produce drugs externally. Seattle Genetics has partnered with Bayer, Genentech, and Takeda Pharmaceuticals.
Siegall is an excellent administrator, and he has displayed this for the past two decades that he has been the head of Seattle Genetics. He led the firm in having a successful IPO in 2001. Clay has also ensured that the company gets sufficient funding from private and public sources. Under his leadership, the Seattle Technologies researchers have developed customized cancer therapies that have penetrated the local and international markets.
The experience that Clay Siegall has gained the past three decades that he has been a biotechnology researcher has made him be considered as an intelligent scientist. Companies such as Biopharmaceuticals, Mirna, and Ultragenyx Therapeutics have appointed him to serve as a member of their boards. During his time at Seattle Genetics, he has successfully developed several drugs and has 15 patents. Under his management, the company made sells that added up to more than $418 million in 2016. The value of its shares had grown to $66 per share by mid-May. Seattle Genetics has raised a lot of money from the commercialization of a drug that is called Adcetris. The cost of using the drug per annum is between $230,000 and $330,000.